ABCLAbCellera Biologics Inc.
$12.55+178% 1Y
$12.55
$2.7852 weeks$14.83
Is the price fair?
What ABCL's price assumes
AbCellera Biologics Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 30.8× revenue.
30.8
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.27
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 2.27
- EV / EBIToperating margin −340%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $2.03B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.